When CRT is
Not an Option
Barostim™ is an option for heart failure patients with reduced ejection fraction that uses autonomic stimulation to significantly improve symptoms
Barostim NEO is a New HFrEF Treatment Option for Heart Failure Patients
1. Yancy CM, et al. Circulation. 2013;128: 2013;128:e240–e327; 2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050. Accessed March 30, 2021; 3. CVRx data on file.
Barostim Rebalances the Autonomic Nervous System
Barostim™ Baroreflex Activation Therapy (BAT™) works by electrically stimulating carotid baroreceptors and, in turn, the baroreflex. This triggers the autonomic nervous system to regulate heart, kidney and vascular function through both sympathetic and parasympathetic pathways.
The Barostim System
Baroreflex Activation Therapy is delivered by the BarostimNEO™, an implantable pulse generator (IPG) designed to deliver continuous electrical stimulation to carotid baroreceptors.
The Barostim System comprises the Barostim NEO IPG, the Carotid Sinus Lead and a simple, intuitive Programmer.
Simple Implant Procedure
The Barostim System is implanted in a simple and safe surgical procedure. The Carotid Sinus Lead is sutured to the carotid sinus after a simple mapping procedure.
The BarostimNEO generator is inserted in a standard device pocket. Procedures typically take less than an hour and are usually performed on an outpatient basis.
The system contains no hardware in the heart or vasculature.